stockrowTravere Therapeutics, Inc.
TVTX Healthcare Biotechnology
Travere Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $490.7 million, up 110.5% from fiscal 2024.
- Revenue
- +36.2%
- EPS
- −290.7%
- Free cash flow
- +6,379.8%
- Total debt
- +93.8%
Quarter to September 2026, against a year earlier
Follow TVTX
Alert me
Travere Therapeutics, Inc. (TVTX) Gross margin
Travere Therapeutics, Inc.'s gross margin over the twelve months to 30 September 2026 was 98.5%, up 0.6 percentage points from fiscal 2025 (97.9%). Over the past ten years it has ranged from 92.1% (fiscal 2023) to 97.9% (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 68.5% and above the Healthcare sector median of 54.5%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 97.9% | 1.21 |
| FY2024 | 96.7% | 4.56 |
| FY2023 | 92.1% | (3.84) |
| FY2022 | 96.0% | (1.14) |
| FY2021 | 97.1% | 0.19 |
| FY2020 | 96.9% | (0.10) |
| FY2019 | 97.0% | 0.38 |
| FY2018 | 96.6% | (1.04) |
| FY2017 | 97.7% | 1.08 |
| FY2016 | 96.6% | (1.22) |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 98.7% | 0.00 |
| Jun 2026 | 98.7% | 0.25 |
| Mar 2026 | 98.5% | 0.44 |
| Dec 2025 | 98.0% | (1.01) |
| 43 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| CRSP CRISPR Therapeutics AG compare | 100.0% |
| DNTH Dianthus Therapeutics, Inc. compare | 100.0% |
| TVTX Travere Therapeutics, Inc. | 98.5% |
| LEGN Legend Biotech Corporation Sponsored ADR compare | 56.6% |
| COGT Cogent Biosciences, Inc. compare | 0.00% |
| ERAS Erasca, Inc. compare | 0.00% |
| DFTX Definium Therapeutics, Inc. compare | 0.00% |
| EWTX Edgewise Therapeutics, Inc. compare | 0.00% |
| MANE Veradermics Incorporated compare | — |
| Biotechnology industry median | 68.5% |
| Healthcare sector median | 54.5% |
| Market median | 46.0% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on TVTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement